Mavacamten gains FDA approval for symptomatic obstructive HCM in pediatric and adult patients
Article excerpt
Highlighted: the sentence this signal was extracted from
Photo from AHA 2022. The U.S. Food and Drug Administration (FDA) expanded the indication for Bristol Myers Squibb's mavacamten (Camzyos) to improve functional capacity and symptoms in obstructive hypertrophic cardiomyopathy (oHCM) in both adult and pediatric patients. The company said this expanded indication offers a new treatment option for patients with a significant unmet need. Mavacamten first gained FDA clearance in April 2022 for adults with symptomatic NYHA class II-III oHCM heart failure, but the new indication will broaden the patient populations that can be treated. The indication also allows earlier interventions, rather than waiting for patient conditions to worsen over time. The drug is now the only FDA-approved therapy for the treatment of oHCM in a pediatric population. The FDA indication for children is for use in patients weighing 30 kg (66 lbs) or more. "Today's approval marks an important milestone for young patients and families who are facing a serious cardiovascular disease with significant unmet medical need," Al Reba, senior vice president, immunology and cardiovascular commercialization, Bristol Myers Squibb, said in a statement. "For young patients living with this disease, the burden on daily life can be substantial during a critical stage of development, and we are proud to help bring an innovative new treatment option to this community." The...
Keep reading with a free account
The rest of this article, and every signal for Bristol Myers Squibb, is in your free account.
